Raymond James Trust N.A. Has $1.12 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Raymond James Trust N.A. boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,064 shares of the biopharmaceutical company’s stock after purchasing an additional 30 shares during the period. Raymond James Trust N.A.’s holdings in Regeneron Pharmaceuticals were worth $1,119,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Quent Capital LLC increased its position in Regeneron Pharmaceuticals by 5.1% during the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 19 shares during the last quarter. CreativeOne Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $200,000. Gamco Investors INC. ET AL acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $230,000. Gabelli Funds LLC boosted its position in Regeneron Pharmaceuticals by 3.0% during the first quarter. Gabelli Funds LLC now owns 1,859 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 54 shares during the period. Finally, Kennedy Capital Management LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $5,210,000. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on REGN shares. Citigroup initiated coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price objective for the company. Leerink Partners restated a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Barclays cut their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 0.9 %

NASDAQ:REGN opened at $738.00 on Monday. The company has a market cap of $81.10 billion, a price-to-earnings ratio of 18.26, a P/E/G ratio of 2.87 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock’s fifty day moving average price is $945.07 and its two-hundred day moving average price is $1,027.53. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.